Copay Assistance Is Meant To Defray Patient Drug Costs. Some Insurers Keep It Instead.

Financial assistance from drugmakers intended to ease the burden of high medication costs is often being retained by some insurers instead of being passed on to patients, leaving them to cover the full cost themselves. This practice, known as "copay accumulator programs," sidesteps insurance plan limits, forcing patients to meet higher deductibles and out-of-pocket costs. The implications are significant as it undermines the purpose of the assistance programs, potentially deterring patients from adhering to their prescribed treatments due to financial strain. This issue highlights a growing concern in healthcare where the cost-sharing strategies of insurers can directly impact patient health outcomes and access to necessary medications.